Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Myelodysplastic Syndromes 7Leukemia 7Multiple Myeloma 5Lymphoma, Non-Hodgkin 5Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, Mantle-Cell 4Hodgkin Disease 4Waldenstrom Macroglobulinemia 3Sezary Syndrome 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Leukemia, Myelomonocytic, Chronic 3Immunoblastic Lymphadenopathy 3Hematologic Neoplasms 3Burkitt Lymphoma 3Recurrence 2Primary Myelofibrosis 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Blast Crisis 2Thrombocytosis 1

Interventions

thymoglobulin 1selinexor 1fludarabine 1Rituximab 1Panobinostat 1Melphalan 1Levetiracetam 1Daunorubicin 1Cytarabine 1Cyclophosphamide 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chromosome Aberrations × Panobinostat × Other hematologic neoplasm × Clear all
NCT01242774 2020-12-19

Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)

Novartis

Phase 1 Completed
46 enrolled
Other hematologic neoplasm

Chromosome Aberrations, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡